Concepedia

Xiaoyun Li

XL

Statistics

Publications

50

Citations

11.6K

H-Index

25

Active since

2012

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Memorial Sloan Kettering Cancer Center

Sun Yat-sen University

Sun Yat-sen University Cancer Center

University of California, San Francisco

Xiaoyun Li is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

2012–2023

50

Publications

50

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text

, , +17

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok et al. · The Lancet · 2014 · 1.8K citations

, , +17

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Antoni Ribas, Igor Puzanov, Reinhard Dummer et al. · The Lancet Oncology · 2015 · 1.6K citations · Full text

, , +15

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Antoni Ribas, Omid Hamid, Adil Daud et al. · JAMA · 2016 · 1.1K citations · Full text

, , +17

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 794 citations

, , +17

1–5 of 50